- Home
- MGTX vs ABSI Comparison
MGTX vs ABSI Comparison
Compare MGTX & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- ABSI
- Stock Information
- Founded
- MGTX 2015
- ABSI 2011
- Country
- MGTX United States
- ABSI United States
- Employees
- MGTX N/A
- ABSI N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- MGTX Health Care
- ABSI Health Care
- Exchange
- MGTX Nasdaq
- ABSI Nasdaq
- Market Cap
- MGTX 302.6M
- ABSI 335.9M
- IPO Year
- MGTX N/A
- ABSI 2021
- Fundamental
- Price
- MGTX $4.18
- ABSI $3.90
- Analyst Decision
- MGTX Strong Buy
- ABSI Strong Buy
- Analyst Count
- MGTX 2
- ABSI 5
- Target Price
- MGTX $22.50
- ABSI $8.40
- AVG Volume (30 Days)
- MGTX 163.7K
- ABSI 940.8K
- Earning Date
- MGTX 11-12-2024
- ABSI 11-12-2024
- Dividend Yield
- MGTX N/A
- ABSI N/A
- EPS Growth
- MGTX N/A
- ABSI N/A
- EPS
- MGTX N/A
- ABSI N/A
- Revenue
- MGTX $8,122,000.00
- ABSI $3,250,000.00
- Revenue This Year
- MGTX $133.83
- ABSI $10.42
- Revenue Next Year
- MGTX $655.34
- ABSI $213.22
- P/E Ratio
- MGTX N/A
- ABSI N/A
- Revenue Growth
- MGTX 26.87
- ABSI N/A
- 52 Week Low
- MGTX $3.49
- ABSI $1.11
- 52 Week High
- MGTX $7.60
- ABSI $6.72
- Technical
- Relative Strength Index (RSI)
- MGTX 53.57
- ABSI 44.01
- Support Level
- MGTX $3.86
- ABSI $3.36
- Resistance Level
- MGTX $4.09
- ABSI $4.23
- Average True Range (ATR)
- MGTX 0.18
- ABSI 0.27
- MACD
- MGTX 0.04
- ABSI -0.07
- Stochastic Oscillator
- MGTX 100.00
- ABSI 32.26
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.